Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2026-02-10 Earnings Release
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Earnings Release 2025
Earnings Release Classification · 1% confidence The document is a comprehensive financial report for AstraZeneca covering the full fiscal year (FY) and Q4 2025. It includes detailed financial statements, revenue summaries, performance highlights, guidance, and a table of contents referencing consolidated financial statements and notes. It is clearly a full-year financial report rather than a simple earnings release or announcement, as it contains extensive tables, notes, and detailed financial breakdowns. Q4 2025
2026-02-10 English
6-K Filing
Foreign Filer Report
2026-02-10 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-06 English
SCHEDULE 13D/A Filing
Major Shareholding Notification
2026-02-06 English
Update on Saphnelo subcutaneous administration
Regulatory Filings Classification · 1% confidence The document is an official regulatory announcement from AstraZeneca PLC distributed via the London Stock Exchange's RNS (Regulatory News Service). It provides a specific update regarding a US FDA regulatory review (a Complete Response Letter) for a drug application. While it contains detailed medical and clinical trial information, it is fundamentally a regulatory news announcement rather than a full financial report, investor presentation, or legal proceeding document. It fits the definition of a Regulatory Filing (RNS) as it is a standard corporate announcement disseminated through a primary information provider.
2026-02-03 English
6-K Filing
Foreign Filer Report
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.